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1INTRODUCTION
Prostate cancer is the second most common cause of cancer and the
sixth leading cause of cancer related death in men worldwide1. It is
essentially a disease of elderly men more than 65 years of age. Previously it
was thought that prevalence of prostate cancer in India is far lower as
compared to the western countries but with the increased migration of
population from rural to urban, increase in awareness, and accessibility to
medical care, more new cases of prostate cancer are being picked up and  it
becomes vivid that we are not much behind to the rate from western
countries. As the most frequent histological subtype, prostatic acinar
adenocarcinoma has number of benign mimickers including prostatic or non-
prostatic lesions and normal structures which may lead to erroneous
diagnosis and inappropriate treatment. It is very important to be aware of the
existence of these mimickers and to recognize their histological features.
Differentiation of prostatic adenocarcinoma from benign prostatic lesions
and hyperplasia sometimes can’t be done on the sole basis of morphologic
findings. In these cases diagnosis can be made according to the presence or
absence of basal cell layer considering the fact that in prostatic
adenocarcinoma there is no basal cells but benign lesion shows encirclement
by this basal cell layer. Hence, using basal cell immunohistochemistry
markers like p63 seems to be useful in distinguishing these two important
categories of prostatic lesions. Another useful marker detectable by
2immunohistochemistry is alpha methyl acylcoA racemase(AMACR), an
enzyme selectively expressed in neoplastic glandular epithelium.
Cocktails of antibodies directed against basal cell markers and
AMACR are particularly useful in evaluating small foci of atypical glands,
and substantiating a diagnosis of minimal adenocarcinoma. The present
study is carried out with the aim to evaluate the utility and expression of
immunohistochemistry markers in differentiating prostatic adenocarcinoma
from benign mimickers and in resolving morphologically suspicious foci on
TURP and needle core biopsies.
3AIM
To determine the effectiveness of immunohistochemistry in
differentiating prostatic adenocarcinoma from cancer mimickers.
OBJECTIVES
1. To study the expression of antibodies against p63 and AMACR using
immunohistochemistry and to determine the effectiveness of these markers
in differentiating prostatic adenocarcinoma from cancer mimickers.
2. To find out the correlation of AMACR expression with Gleason grading of
prostatic adenocarcinoma cases.
3. Also to find out the expression of p63 and AMACR antibodies in benign
glands and premalignant lesions.
4REVIEW OF LITERATURE
ANATOMY OF PROSTATE
The human prostate gland is a part of male reproductive system. It is a
walnut-shaped gland, measures about 5 cm x 4 cm x 3 cm and weighs 20
gms upon maturity. The gland is found low in the pelvis minor, surrounds
the bladder neck and the first part of the urethra, and is posterior to the
symphysis pubis. The gland lies ventral to the ampulla of the rectum, where
the posterior portion of the prostate can be easily palpated.
The prostate has three major anatomical zones: the peripheral zone
(PZ), the central zone (CZ) and the transition zone (TZ), occupying 65%,
25% and 10% respectively, of the prostate volume2. The biology of these
regions differs, which is important for the development of cancer & other
histological lesions. The central zone is located at the base of the prostate
and surrounds the ejaculatory ducts, extending out from the verumontanum
in a wedge-shaped fashion. The transition zone, which surrounds the
proximal prostatic urethra, and is found at the junction of the proximal and
distal segments of the urethra. The transition zone is important in that it can
undergo hyperplasia, resulting in the formation of nodules known as benign
prostatic hyperplasia which may lead to clinical symptoms of prostatism
such as urinary frequency, hesitancy and dribbling. The largest zone, which
is the peripheral  zone, completes the remaining part of the prostate, and is
also where carcinoma of the prostate predominantly occurs.
5Figure:1 Anatomy of prostate
PHYSIOLOGY
The main function of the prostate is the secretion and storage of slightly
alkaline seminal plasma that is added to semen upon ejaculation. A large part
of the ejaculate consists of prostatic fluid, which serves to nourish and
protect the semen. Prostatic secretions contain numerous enzymes and
substances including proteases such as Prostatic specific antigen, acid
phosphatase, potassium, zinc, citric acid, spermine, amino acids, and
prostaglandins. These secretory products enhance fertility by promoting
sperm viability and motility. An antimicrobial role has been suggested for a
few of these substances such as zinc, spermine, and proteases. Testosterone,
which is secreted by the testis, is metabolised to dihydrotestosterone by 5-
alpha reductase in the prostate.
6HISTOLOGY
Microscopic study of, adult prostate in men in  between third to fifth
decades comprises of branching duct-acinar glandular system that is
embedded in a dense fibromuscular stroma.
Figure: 2 Histology of Prostate
The normal epithelium of the prostate is classically defined as having two
cell layers: a luminal or secretory cell layer requiring androgens for growth
and survival and an androgen insensitive basal cell layer. The basal cell
layer separates the secretory cells from the basement membrane and is
nearly continuous which is a diagnostic criterion for benign conditions.
For the diagnosis of invasive carcinoma, the complete absence of basal
cells is an important finding. The third cell type in normal prostatic
epithelium are neuroendocrine cells (NE). Stroma contains cells such as
7skeletal cells, smooth muscle cells and also fibroblasts and endothelial
cells.
EMBYOLOGICAL DEVELOPMENT
Androgens are necessary for the development and function of the
prostate, that includes i) testosterone, synthesized in the testes
ii) dehydroepiandrosterone, synthesized in the adrenal glands and
iii) dihydrotestosterone, that is converted from testosterone within the
prostate. The prostate is developed from the urogenital sinus and is
recognizable at the period of 9 to 10 weeks during embryological
development.
There is an infantile resting period after birth until the age of 10 to
12 years and then a pubertal maturation period until age 18 years.
Eventhough there is no change in size of  prostate gland during the resting
period, duct formation and solid budding continues. The pubertal period is
marked by substantial androgen-driven increase in gland size, further
branching and differentiation of immature prostatic epithelium into the
adult-type basal and secretory cells. It has been proposed that the central
zone of the prostate is of mesodermal Wolffian duct origin. In this sense,
the prostate gland is of dual embryonic derivation.
8PROSTATE CANCER
Cancer development
Prostate cancer development and progression is a multistep process.
Prostate cancer development occurs due to the loss of balance between cell
proliferation rate and programmed cell death (apoptosis).
Figure:3 Tumour Progression
(This figure shows the gradual transformation of a normal gland into a
more undifferentiated structure. Basal cells tend to disappear, the glands
become smaller, lumina are not well defined and eventually there are only
cancer cells, scattered or forming solid sheets)
In Prostate cancer, tumour cells have been believed to originate from
luminal epithelial cells since they are dependent on androgens and express
luminal cell markers. The development of prostate cancer (PC) occurs
through the accumulation of genetic and epigenetic changes, leading to an
inactivation of tumor suppressor genes and activation of oncogenes3. These
alterations most likely take several decades and cancer development can be
considered a continuous transformation from benign cells, cancer precursors
and finally malignant cells4.
9Important premalignant lesions of prostatic adenocarcinoma which
includes: prostatic intraepithelial neoplasia (PIN) and proliferative
inflammatory atrophy (PIA). Among these two lesions, PIN exhibits more
convincing correlation with cancer5,6,7,8. PIN is considered to be an
intermediate stage from benign epithelium to carcinoma. Histologically
PIN is very similar to prostate cancer, with the exception that the basal
layer is discontinuous but still present9,10. Prominent nucleoli are vital for
the diagnosis. PIN is classified into low-grade and high-grade PIN (LGPIN
and HGPIN)5,11.
These lesions are converted into malignant neoplasms through many
sequence of changes. Initially they are limited to the prostate, after that
infiltrates the prostate capsule, involve the surrounding tissues and finally
form metastases.
PIA consists of proliferative epithelial cells without the ability to
differentiate into common secretory cells2,4. It is not yet clear that whether
there is any significant correlation between PIA and prostatic
adenocarcinoma, eventhough some relationship between PIA and cancer is
observed.
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Figure: 4 Progression and Development of prostatic carcinoma3
PIA is more common in the peripheral zone12,2,13. PIA is often seen close to
PIN or cancerous lesions12,13,14. PIA is associated with chronic
inflammation, which is known to have a role in cancer development15.
However, whether PIA is a premalignant lesion or not, remains to be further
elucidated, as there are conflicting reports16,17,18.
Risk factors
Age, family history and race are  some of the definitive risk factors
in the development of prostate cancer .
Clinically, carcinoma of the prostate is most often detected in men
over 60 years of age and it is rare before 40 years of age.
The second most important risk factor is a family history of the
patient. About 25% of men with prostate cancer have a known positive
family history. The degree of risk is related to the age of the relatives at
diagnosis and the number of relatives affected. The risk of developing PC
is known to be hereditary, with a reported estimated risk of 27-42 % in
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studies on monozygotic twins19,20,21. The hereditary pattern most likely
follows an autosomal dominant inheritance22. It has been suggested that
patients with familial PC have a worse prognosis than sporadic cases.
Race is a definite risk factor for prostate cancer incidence and
detection. Variations in gene promoter hypermethylation may potentially
cause racial differences in prostate cancer pathogenesis. Promoter regions
of genes which are normally unmethylated become methylated in cancer
cells which is caused by 5’- cytosine of the dinucleotide pair (CpG) being
covalently bound by methyl group, resulting in silencing of the  tumor
suppressor and  regulator gene expression.
Probable risk factors for development of prostate cancer include diet
and steroid hormones. An interesting hypothesis exists about zinc and
prostate cancer according to which uptake of zinc may be different in racial
groups. This suggestion is based on the evidence that the normal prostate
contains high amounts of free zinc ions that are secreted into the seminal
fluid. In other words, the loss of ability to retain normal intracellular levels
of zinc is an important factor in the development and progression of
prostate cancer. It is also noted that the dietary zinc supplements are mostly
nontoxic.
The strongest dietary link to prostate cancer development is high fat
intake23. Dietary fat could increase PC risk via one or more mechanisms,
such as lipid peroxidation leading to the production of DNA-damaging free
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radicals and alteration of serum sex hormone levels. Increased dietary fats
and calories leads to secretion of growth hormone and insulin causing
Insulin growth factor synthesis that result in  reduced cell apoptosis and
increase in cellular proliferation.
In contrast, intake of fruits and vegetables, particularly tomatoes,
may decrease the risk of development of prostate cancer24. Lycopene, a
carotenoid antioxidant, is an agent in tomatoes that has been associated
with this diminished risk25.
Intake of soya bean containing isoflavones can be correlated with
decreased risk of prostate cancer. The mechanism of action of these
isoflavones shown in some experimental studies is by inhibiting tyrosine
kinase enzymes, which play a part in cell proliferation and angiogenesis26.
Selenium and vitamin E are other micronutrients being studied that
have been shown to reduce the risk of prostate cancer27.
Steroid hormones are considered to be an important risk factor in
prostate carcinoma which includes sex hormones particularly testosterone
and vitamin D. Increased serum vitamin D levels can lower the risk of
development of prostate cancer especially in tumours with high grade28.
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DIAGNOSIS
1. Digital rectal examination
The initial examination of the prostate, in patients with urogenital
symptoms, is often digital rectal examination(DRE). This is a simple
diagnostic method with minimal complications29. Although the detection
rate of tumors using DRE is not as high as for serum PSA measurements, a
combination of the two methods has higher detection rate than each alone30.
Tumors discovered through DRE are often more advanced than PSA-
detected cancers30.
2. Tissue biopsy
Tissue biopsy is necessary to find out Gleason score which is essential
for choosing the appropriate treatment. Biopsy is performed on the basis
of abnormal serum PSA or DRE31. Most studies show a higher detection
rate with more number of biopsies32. Often the procedure is repeated at
intervals if PSA levels indicate that cancer may be present although biopsies
are negative. Known complications of transrectal biopsies include infection,
bleeding, haematuria, haemospermia and urinary difficulties33,34 . Recently,
Trans rectal ultrasound (TRUS)-guided core biopsies have emerged as a
method choice for PC diagnosis. Core biopsies can be combined with
immunohistochemistry which increases the diagnostic accuracy and adds
clinically important information on extent of disease and Gleason score.
14
Gleason Grading System
The Gleason grading system used for prostate cancer was developed
in 1966 by Donald F.Gleason, whereby the cancer was graded based on
the morphology of the tumour.
Gleason grading system includes 5 grades given to each primary and
secondary histological pattern. Each grade describes a glandular pattern,
with grade 1 being the best differentiated and grade 5 representing the
worst or least differentiated pattern. The two predominant patterns are
graded and added to obtain Gleason score. It has minimum score of 2and
maximum score of 10, with 5-8 range being the commonest.
A study reported that low Gleason grade tumours were usually
located in the transition zone of the prostate gland, and higher Gleason
grade tumours were often found in the peripheral zone and associated with
worse prognosis35.
Gleason grade 1 tumours consist of circumscribed nodules of
uniform, single glands which are closely packed. The glands in Gleason
grades 1 and 2 are also larger than those of higher Gleason grades.
Gleason grade 1 and 2 patterns are associated with cells with abundant and
pale cytoplasm36.
15
Gleason grade 2 tumours are rather well circumscribed but tend to
infiltrate beyond the lobular margins into the nearby non-neoplastic gland.
The glands are loosely arranged and less uniform that those in grade 1.
FIGURE 5-Gleason grading
Gleason grade 3 tumours infiltrate within non-neoplastic prostatic
lobules. The sizes and shapes of the glands are more variable. The glands
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can be large and cribriform, and are considered Gleason grade 3 as long as
the glands are not coalescent and still maintain their rounded contours.
Gleason grade 4 glands, on the other hand, are coalescent and fused,
with some abortive glandular profiles. Cribriform patterns can be seen but
the contours are now irregular and the glandular outlines larger. These cells
may have pale to clear cytoplasm.
Gleason grade 5 glands are made up of sheets, cords, single cells or
solid nests. The glands have sparse or no lumina. Comedonecrosis is also
seen in Gleason grade 537.
The critical importance of pathologic assessment of prostate cancer
for treatment and prognostication calls for reproducibility, consistency and
consensus on Gleason grading.
Prostate Specific Antigen (PSA) Screening and Pitfalls
For many years now, serum PSA has been the method of choice for
screening the prostate cancer. And it has also been widely accepted that a
serum PSA level of more than 4ng/ml is usually indicative of probable
prostate cancer38.
There is still controversy regarding the age to begin and stop PSA
screening, the threshold value to consider biopsy, screening a population
who are at higher risk to develop the cancer, and also other existing
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diseases that might affect the PSA levels. Some of these issues remain
unresolved. As such, overdiagnosis may occur, resulting in unnecessary
aggressive treatment or invasive procedures, which could affect the
patient’s overall well being in addition to the possible financial and
psychological burden.
It has also been mentioned that total PSA is not a “classic” tumour
marker because an increase in level of PSA is not directly correlated with
worse stages or grades38. As PSA is more prostate specific, rather than
cancer specific, a mild to moderate increase can be commonly present in
benign conditions like  prostatitis and in benign prostatic hyperplasia
(BPH).
In addition, a number of prostate cancers are present in patients with
PSA values within normal range39. There have also been reports that PSA
levels can decrease with increasing Gleason scores38.
Serum PSA tests may also be used to monitor various treatments of
prostate cancer in deciding whether post-therapy biopsies are needed.
Elevated serum PSA levels following radical prostatectomy (0.2 ng/mL)
indicate recurrent or persistent disease.
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PREMALIGNANT LESIONS OF PROSTATE
Prostatic intraepithelial neoplasia is the most common precursor
lesion of prostatic carcinoma. The only method of detection is biopsy.
Prostatic intraepithelial neoplasia (PIN) does not significantly elevate
serum prostate-specific antigen concentration and cannot be detected by
ultrasonography.
As most cases of PIN progresses to adenocarcinoma, its presence
needs repeated biopsy for diagnosing invasive carcinoma. PIN, patient age
and serum  PSA concentration were jointly highly significant predictors of
cancer, with PIN providing the highest risk ratio. Carcinoma will develop
in most patients with PIN within 10 years. PIN can be classified into low
grade PIN and high grade PIN.
The incidence and extent of PIN appear to increase with patient
age. In young men, mostly the PIN foci are low grade. With advancing age,
the frequency of HGPIN increases. The PIN is found predominantly in the
peripheral zone of the prostate (75%-80%), rarely in the transition zone
(10%-15%), and extremely rare in the central zone (<5%).
PIN may involve part of the lumen of a duct or the entire unit.
PIN is characterized by cellular proliferations within preexisting ducts  and
acini with cytologic changes mimicking cancer, including nuclear and
nucleolar enlargement. At the onset, the epithelial proliferation is manifest
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as increased cellularity and pseudostratification, but as the process
progresses, intraluminal papillae may develop.
1. Low grade prostatic intraepithelial neoplasia(LGPIN)
Low grade prostatic intraepithelial neoplasia is quite difficult to
recognize, as it has common features with normal and hyperplastic
epithelium. It has the similar morphology as HGPIN, but most of the cells
lacked prominent nucleoli. More prominent nucleoli, when observable,
comprise less than 10% of dysplastic cells40,41. The basal cell layer
normally surrounding secretory cells of ducts and acini remains intact42,43.
The distinction between HGPIN and LGPIN is based primarily on the
extent of cytological abnormalities (that is prominence of the nucleoli) and
secondarily on the degree of architectural complexity44,45. Immunostaining
studies of microvessel density may help to differentiate HGPIN from
LGPIN46.
2. High grade prostatic intraepithelial neoplasia(HGPIN)
Morphologically, there are four basic patterns of HGPIN: flat,
tufting, micropapillary and cribriform47. These patterns often merge with
each other. Other unusual patterns of PIN include the signet ring cell
pattern, small cell neuroendocrine pattern, mucinous pattern,
microvacuolated (foamy gland) pattern, and inverted (hobnail) pattern. The
most common are the papillary and tufting patterns, less frequent is the
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cribriform pattern. Other than diagnostic utility, these architectural patterns
have no known clinical significance.
Several studies indicate that HGPIN is the most likely precursor
lesion of  PC40,42,43,48 because of the similarities between them:
1 Age. The frequency of HGPIN and PC increase with age49
2 Coexistence. HGPIN often coexist with PC in the same samples40.
3 HGPIN is predominantly located in the peripheral zone, the zone in which
most clinically important prostate carcinomas are found49.
4 Morphological similarities. HGPIN is characterized by cellular crowding
and stratification. There is inequality in cell and nuclear size.
Hyperchromatism is frequently seen with an enlarged nucleus, often
containing prominent nucleoli. These changes are also seen in Gleason
grade 1-4 PC50.
5 Histologically, the atypia observed in HGPIN is virtually indistinguishable
from that of PC except that in HGPIN the basal membrane is still intact51.
As HGPIN progresses, the likelihood of basal cell layer disruption
increases. In PC, there is complete loss of the basal cell layer.
6 Both in HGPIN and PC, collagenase type IV expression is increased. This
enzyme is responsible for basal membrane degradation and thus facilitates
invasion52,53.
7 Molecular and genetic similarities- Several genetic changes encountered in
PC cells can be found in HGPIN54.
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8 PC and HGPIN have similar proliferative and apoptotic indices55.
Atypical Glands Suspicious for Malignancy
The term atypical small acinar proliferation (ASAP) is used to
describe atypical glandular proliferations that do not reach the threshold to
be diagnosed as cancer either qualitatively or quantitatively. ASAP is the
most frequent indication found by immunohistochemistry in prostatic
needle biopsies. This diagnosis does not imply a specific pathologic entity,
but only implies that the glandular changes are suspicious for malignancy.
Lesions that may be given such a diagnosis are a focus of small glandular
proliferation with lack of prominent nucleoli, lack of nuclear enlargement,
artefactual distortion, too few glands to be sure, depletion of tissue,
inability to do basal cell stains, and so forth56-59. The frequency of this
diagnosis in contemporary large prostate biopsy series is quite variable,
ranging from less than 1% to 23%, with an average around 5%. In one
study indicate that invasive carcinoma was identified in 48.9% of patients
on repeat biopsy when the patient had a diagnosis of atypical glands
suspicious for malignancy. Immunohistochemical staining with basal cell
markers(34βE12 and p63) and AMACR is very useful.
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PROSTATIC ADENOCARCINOMA
Carcinomas may arise in any zone of the prostate, but the
distribution is different in each zone; 60% arise in the peripheral zone, 24%
in the transtition zone and 8% in the central zone60. Adenocarcinomas
rarely can arise from ectopic prostate tissue61.
Adenocarcinoma is the most common malignancy of the prostate
gland, accounts for more than 25% of all malignancies in men, and is the
second leading cause of death after lung carcinomas62. The majority are
multifocal (60-90%)63 and exhibit an acinar or mixed acinar and ductal
growth pattern.
The rule of “three toos” (too small glands, too crowded glands with
back-to-back arrangement and too clear glands) is very useful in
identifying prostatic carcinoma in biopsy and TURP specimens. To
confirm the diagnosis of carcinoma, three diagnostic criteria including
nuclear enlargement, prominent nucleoli and lack of basal cells should be
present. In carcinoma, the size of the nucleoli is often at least 1 micron in
diameter.
Several other features have been shown to be helpful for diagnosis of
carcinoma - intraluminal crystalloids, blue mucin, glomerulations,
mucinous fibroplasia (collagenous micronodules) and circumferential
perineural invasion.
23
There are several benign conditions which mimic adenocarcinoma.
In these situations, overexpression of AMACR by tumour cells and
complete loss of basal cells which are evaluated by HMWCK(34βE12),
CK5/6 and p63 immunohistochemistry provide confirmatory evidence for
the diagnosis.
Variants of Prostatic adenocarcinoma
Variants of prostatic adenocarcinoma account for 5% to 10% of all
adenocarcinomas. Recognition of these variants is important because many
have a poorer prognosis than conventional acinar prostate adenocarcinoma.
1. Mucinous adenocarcinoma
The criteria for primary mucinous adenocarcinoma of the prostate
are (a) at least 25% of the tumor should show aggregates of cells floating in
lakes of extracellular mucin, (b) No signet ring component or significant
intercellular mucin should be present, (c) extraprostatic primary tumor sites
should be ruled out or tumor cells should be positive for PSA and Prostatic
acid phosphatase (PAP) immunostaining. When adhering to these criteria,
this is an extremely rare tumor. No pure mucinous adenocarcinoma of the
prostate has been reported so far.
2. Signet Ring Cell Carcinoma of the Prostate
Primary signet ring cell carcinoma of the prostate is extremely rare.
While Gleason grade 5 carcinomas can show single cells with signet ring
morphology, signet ring cells should comprise more than 25% of neoplastic
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cells to render the diagnosis of signet ring cell carcinoma. It is imperative
that metastatic involvement from another site (i.e. stomach, bladder, colon,
etc.) to be ruled out.
3. Ductal Adenocarcinoma
It is Previously known as “Endometrioid adenocarcinoma”
Histologically these tend to show two main patterns. One consists of
true papillary fronds with well established fibrovascular cores lined by high
columnar cells exhibiting a variable degree of cytologic atypia and
prominent nucleoli. Second pattern consists of an intraductal proliferation
of large, back to back glands imparting a somewhat cribriform appearance.
In both cases the surrounding stroma often appears altered or fibrotic. The
main differential diagnosis is high grade prostatic intraepithelial neoplasia
(HGPIN).
4. Pseudohyperplastic and foamy gland carcinoma
These variants of acinar adenocarcinoma are best characterised by
striking tendency to mimic benign processes such as adenosis or foci of
crowded benign glands. So it is helpful to perform immunoperoxidase
stains to confirm diagnosis.
Pseudohyperplastic carcinoma is composed of glands showing
features commonly associated with benignity including large, branched
glands with papillary infolding and even corpora amylacea. Clues which
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identify the lesion as malignant are nuclear enlargement, macronucleoli,
mitoses, intraluminal crystalloids, and sometimes the presence of adjacent
PIN.
In contrast, foamy gland carcinoma often has a worrisome,
infiltrative pattern with rather bland cytology. Foamy gland carcinomas
are characterised by xanthomatous cytoplasm because of accumulation of
lipids and small hyperchromatic nuclei with inconspicuous nucleoli. The
behaviour of foamy gland carcinomas is often aggressive, even in the
presence of deceptively innocuous microscopic features.
5. Prostatic adenocarcinoma with atrophic features
This variant mimics a benign hyperplastic change and composed of
tumor cells with an attenuated cytoplasm and nuclei occupy almost the
entire cell height. These cells are identifiable as malignant because of their
infiltrative pattern of growth, nuclear enlargement, macronucleoli.
6. Small Cell Carcinoma of the Prostate
Small cell carcinoma arising primarily from prostate is very rare. It
is a highly aggressive malignant tumour. Small cell carcinoma is composed
of an infiltrate of small  uniform cells showing nuclear molding, stippled
chromatin, and inconspicuous nucleoli. Frequent mitotic figures are noted.
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7. Sarcomatoid carcinoma
Sarcomatoid carcinoma of the prostate is another uncommon variant
of adenocarcinoma with a biphasic appearance, containing carcinoma and a
spindle or pleomorphic sarcomatoid component. Majority of patients have
metastatic disease at the time of diagnosis, and 50% have a history of
prostate cancer treated with radiation or hormonal therapy. Sarcomatoid
carcinoma has poorer prognosis.
8.Lymphoepithelioma like carcinoma
Lymphoepithelioma like carcinoma is an extremely rare variant of
prostate carcinoma. It shows a very close similarity with undifferentiated
nasopharyngeal carcinoma, thats why it is called as“lymphoepithelioma.”
As such, the microscopic picture is that of nests, sheets, cords, or single
malignant cells having large vesicular nuclei with prominent nucleoli in a
background of dense lymphoid population (host reaction) which can
sometimes obscure the carcinomatous nature of the lesion.
9. Squamous/adenosquamous carcinoma
The histology of prostatic squamous carcinoma is composed of
infiltrating nests, strands and sheets of cells with cytologic atypism. The
hallmark features of squamous differentiation includes: individual
cell keratinization, intercellular bridges, and/or keratin pearl formation.
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Adensquamous carcinomas most often show a transition between glandular
and squamous differentiation. Other primary sites should be excluded.
10. Basal cell/adenoid cystic carcinoma
This neoplastic process resembles adenoid cystic carcinoma of the
salivary gland. The key microscopic features are expansile pattern of
growth, multinodularity, a cribriform architecture with luminal-basal
lamina-like material, a surrounding fibromyxoid stroma, common
occurrence of squamous differentiation, and merging with foci of basal cell
hyperplasia. The differential diagnosis includes basal cell hyperplasia,
acinar adenocarcinoma with cribriform pattern of growth, basaloid
carcinoma and true adenoid cystic carcinoma.
Problems associated with diagnosis.
The most of prostate adenocarcinomas can be easily diagnosed; but
difficult cases do exist. First is in the differentiation between well-
differentiated adenocarcinoma from its many benign mimickers and
atypical small-gland proliferation. Second is the threshold for identifying
very small foci of tumor in needle biopsies.
Eventhough numerous criteria that have been validated for the
diagnosis of prostate cancer in previous studies, it is still very difficult in
applying  such criteria on dealing with less number of glands with atypia.
Hence a meticulous systematic approach is necessary.
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The process should involve evaluation of (a) architectural features;
(b)cytologic features; (c) clues that may assist in the diagnosis,such as
bluish acid mucin, crystalloids, collagenous micronodules, glomerulation,
and circumferential perineural invasion, as mentioned before; and (4)
presence of associated high-grade PIN. Caution is warranted if marked
inflammation, budding from apparent benign glands, and artifacts of
crushing or thick sections are present.
Benign mimickers of prostatic adenocarcinoma
Prostate cancer is the most frequent malignant and heterogeneous
neoplasm in males64. Among its all subtypes, prostatic acinar
adenocarcinoma (PAA) is the most common and mostly the cases are
without any symptoms but show an elevated prostate-specific antigen
(PSA) or with symptoms only when the patients have locally advanced or
metastatic lesions65
Generally, it is easy to make a diagnosis of Prostatic acinar
adenocarcinoma by its typical histological and cytological characteristics.
However, sometimes the diagnosis becomes a challenge because numerous
benign or malignant prostatic or non prostatic lesions and normal structures
can be very similar to PAA, especially in a small piece of tissue from
transrectal ultrasound (TRUS)-guided needle biopsy or transurethral
resection of the prostate, which may lead to an erroneous diagnosis and
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inappropriate treatment. So it is very important to be aware of the existence
of these mimickers.
CLASSIFICATION OF BENIGN MIMICKERS OF
ADENOCARCINOMA
1.Atrophy
Simple
Cystic
Post atrophic hyperplasia
Partial atrophy
5.Reactive atypia
Inflammatory
Ischemic
Radiation
2.Prostatic hyperplasia
Basal cell hyperplasia
Benign nodular hyperplasia-
( small gland pattern)
Clear cell cribriform hyperplasia
Sclerosing adenosis
6.Metaplasia
Mucinous
Nephrogenic adenoma
3.Inflammation
Usual prostatitis with preservation
artifacts
Nonspecific Granulomatous prostatitis
Xanthogranulomatous
Prostatitis(xanthoma)
Malakoplakia
7.Histoanatomic structures
Seminal vesicle
Cowper’s gland
Paraganglion
Verumontanum gland
(hyperplasia)
Mesonephric gland
remanants (hyperplasia)
4. Atypical Adenomatous
Hyperplasia (Adenosis)
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Benign mimickers of gleason score2-6 prostatic adenocarcinoma
Atrophy, Adenosis, Basal cell hyperplasia, Radiation atypia,
Nephrogenic adenoma, Seminal vesicle, Cowper glands,Verumontanum
hyperplasia and colonic mucosa are considered as benign mimickers of
prostatic adenocarcinoma with gleason score of 2-6.
Benign mimickers of gleason score 7-10 prostatic adenocarcinoma
Nonspecific granulomatous prostatitis, Clear cell cribriform
hyperplasia, Sclerosing adenosis, xanthoma, Paraganglia and Signet ring
cell lymphocyte are considered as benign mimickers of prostatic
adenocarcinoma with gleason score of 7-10.
I.Prostatic Atrophy
Prostatic atrophy is a common lesion involving the elderly
population. Amongst the mimickers, atrophy and partial atrophy are
commonly misdiagnosed as Prostatic carcinoma. So far the etiology of
atrophy is largely unknown. It is supposed that prostatic atrophy is caused
by age-related physiological changes, nonspecific inflammation, nutrient
deficiency, local compression and anemia, hormonal or radiotherapy
action, and so on. It is usually located in the peripheral zone but may be
present in the transition and central zones as well.
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Microscopically, atrophy can be diffuse or focal. Diffuse atrophy is
typically seen in patients with androgen deprivation therapy. In contrast,
focal atrophy is often sporadic, is sometimes associated with inflammation,
and occurs as heterogeneous patches.
Prostatic atrophy is divided into four categories: simple atrophy,
cystic atrophy, post-atrophic hyperplasia (PAH) and partial atrophy66.
Simple or cystic atrophy and PAH usually involve an entire lobule.
The size and shape of cells are similar to normal cells, except parts
of cells in cystic and dilated glands are flat. PAH is characterized by a
coexistence of atrophic and hyperplastic glands67. Its typical features are a
pile of tightly arranged acini budded from the small atrophic glands.
Commonly, PAH does not show local infiltration or confluent glands.
Microscopically, partial atrophy may be mistaken as PAA. In
contrast to above mentioned atrophic subtypes, partial atrophy shows
lobular or diffused pattern of growth. The cells usually have relatively
scant cytoplasm and irregularly crinkled nuclei without basophilic
appearance at low magnification. Moreover, in about half of the cases,
basal cells are very difficult to be noted or even absent. Apart from, it is
necessary to note that whether the basal cell layer is intact in the atrophic
glands using  IHC markers  as those basal cells show  positivity for high
molecular weight cytokeratin (HMWCK- 34βE12), CK5/6 and p63 marker.
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In cases with partial atrophy the glands may show AMACR expression,
similar to PAA and HGPIN68.
II. Prostatic Hyperplastic Lesions
1.Benign prostatic hyperplasia (BPH)
Benign prostatic hyperplasia is a very common benign lesion with
increasing volume of the prostate. It mainly locates in the transitional and
periurethral zone. BPH commonly presents as large and discrete nodules
caused by hyperplasia of both glandular and stromal components69 .
Histologically, the glands vary from small and crowded glands to
large glands with cystic dilatation and exhibit complicated growth pattern,
including papillary infoldings and branching structure70. It is noted that
medium to large sized glands present in BPH may mimic
pseudohyperplastic adenocarcinoma, which is a variant of PAA, especially
in the tissues obtained from needle core biopsy. However, the tumor cells
of adenocarcinoma usually have malignant nuclear features and the
neoplastic glands lack basal cell layer.
2.Basal Cell Hyperplasia
Basal cell hyperplasia (BCH) of the prostate gland is a relatively
common lesion in hyperplastic prostates being examined in TURP
specimens. BCH occurs in about 23% of whole prostatic tissues and10% of
peripheral zone by needle core biopsy71. BCH usually coexists with BPH
and presents as wellcircumscribed lobules with smooth borders
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Conventional BCH show the features that glands with basal cells
that may be multilayered or forming solid nests of basaloid cells. The basal
cells are showing basophilic cytoplasm and bland nuclei without any
nucleoli or features of pleomorphism. We can easily differentiate this
condition from adenocarcinoma. But the unusual subtypes of this
condition, florid BCH and atypical BCH may simulate PAA.
Microscopically florid BCH shows vast production of basal cells
affecting greater than hundred small packed acini and create a nodule
formation. Atypical BCH is characterised by increased generation of basal
cells which are having nuclei with  conspicuous nucleoli. In both these
conditions we can appreciate the features of atypical nuclei, secretions in
the lumina, hyaline globules within the cytoplasm, even very few
mitosis72,73. Infrequently, the packed glands may exhibit features of
infiltrative growth pattern.
Inspite of all this, the following features such as multilayered cells or
solid nests of basal cells, calcifications, and cellular fibrous stroma  may be
helpful  to find out this condition. It is evident  that IHC staining may be
useful adjunct to confirm this hyperplastic basal cells and exhibits negative
expression of AMACR, PSA and prostatic specific acid phosphatase
(PSAP) markers73,74.
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3.Clear Cell Cribriform Hyperplasia
Clear cell cribriform hyperplasia (CCCH) of the prostate is a rare
form of BPH. It consists of enlarged glands filled with anastomosing clear
cells, which form a cribriform growth pattern. The cells comprising the
central cribriform areas are cuboidal to low columnar secretory-type cells
with uniform round nuclei and clear cytoplasm. They lack nuclear atypia
and nucleolar enlargement. Basal cells are prominently displayed around
the periphery. CCCH may become a pitfall for high-grade PAA with
cribriform pattern. However, the nodular proliferation, bland cytology,
cellular fibrous stroma, and the intact basal cell layer can  be helpful  in the
diagnosis of CCCH75.
4. Sclerosing Adenosis
Sclerosing adenosis is a rare lesion characterized by variable sized or
shaped glands disorderly embed into prominent sclerotic stroma.
Sclerosing adenosis of prostate is very similar to that of breast. It is of both
practical and academic importance to recognize sclerosing adenosis,
because of its remarkable resemblance to adenocarcinoma on histologic
examination and its myoepithelial differentiation. Sclerosingadenosis is not
a premalignant condition and is localized to the transition zone.
It is a benign condition  caused by hyperplasia of both glandular
and stromal components. The lesion presents as nodular with well defined
boundary, but without capsule76.There are both clear secretory cells and
35
amphophilic basal cells in the hyperplastic glands. The cells may have
conspicuous nucleoli and intraluminal acid mucin. Sclerosing adenosis
should be differentiated from small acinar adenocarcinoma.
III.  Inflammation
1.Ordinary prostatitis
Occasionally, needle biopsies with prostatitis of the usual type may
cause diagnostic problems77-79. This is especially true when there is poor
preservation and mechanical (crush) artifacts. In few cases,
immunohistochemical stains (such as keratins, leukocyte common
antigens) are needed for resolving  the differential diagnosis.
2.Non-specific granulomatous prostatitis
Granulomatous prostatitis commonly results in a prostate gland that
feels firm to hard and clinically simulates carcinoma. In biopsy samples,
especially needle biopsies, florid nonspecific granulomatous prostatitis
may simulate carcinoma80,81.
The association of the inflammation with ducts may be absent and
when the inflammatory process is diffuse, high-grade (Gleason 5)
carcinoma needs to be considered. The problem is amplified if poor
preservation or mechanical artifacts are present. The recognition of the
inflammatory nature of the cells along with the association of giant cells
and fibrosis are helpful features. In diagnostically difficult cases,
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immunohistochemical staining with  cytokeratins, prostatic epithelial
markers and lymphohistiocytic markers may be helpful.
3. Xanthogranulomatous prostatitis (xanthoma)
Collections of lipid-laden macrophages in the prostate may cause
diagnostic confusion with the hypernephroid pattern of adenocarcinoma
(Gleason4)82,83.  Xanthomatous histiocytes have small uniform nuclei with
inconspicuous nucleoli. They are frequently admixed with other type of
inflammatory cells. In few situations, we can appreciate distinct population
of foam cells which can create confusion in diagnosis. The problem is
compounded by the fact that some hypernephroid carcinomas do not show
the typical nuclear features of malignancy. They may have small dark
nuclei without prominent nucleoli. In certain cases, to resolve the
diagnostic dielemma,  immunohistochemistry using  stains for epithelial
and prostatic cells, and histiocytes may be helpful.
4.Malakoplakia
Malakoplakia of the prostate is a rare infiltrative lesion characterized
by diffuse sheets of histiocytes, usually admixed with other inflammatory
cells including lymphocytes, plasma cells and neutrophils. When von
Hansemann histiocytes predominates during the early stage of
malakoplakia, this can simulate carcinoma particularly of Gleason pattern4.
The lack of any acinar differentiation and admixed inflammatory infiltrate
37
along with the typical Michaelis–Gutmann bodies will lead to a correct
diagnosis. Loss of expression of cytokeratins and prostatic epithelial
markers and positive staining of CD68 may be helpful indifficult
diagnostic situations.
IV. Acinar Proliferations of the Transition Zone(Adenosis)
Atypical Adenomatous Hyperplasia (Adenosis) AAH, or adenosis
of the prostate, is difficult to distinguish from well-differentiated
adenocarcinoma of the prostate. It belongs to a benign lesion with the
proliferation of small acini. The incidence of AAH varies from 1.5% to
19.6% in transurethral resections of prostate and radical prostatectomies.
AAH is easily misdiagnosed as PAA, particularly in a TRUS-guided
biopsy of the prostate.
AAH is a well circumscribed lesion with lobular appearance.The
glands are small, round, and densely packed. Some of them merge into
larger and complex acini. It may have an expansile or minimally infiltrative
margin, crystalloids, crowded and disorderly glands, and medium-sized
nucleoli, which resemble to low-grade PAA.
There are no macro nucleoli (>3 μm), blue-tinged mucin and
straight luminal borders in AAH, which is the features of PAA. AAH can
focally express (10% of cases), even diffusely express (7.5% of cases)
AMACR76 , it is therefore important to identify that the basal cell layer is
preserved, although basal cells usually are discontinuous or focally present
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in AAH. The results implies it to be a mimicker of adenocarcinoma and
must be considered an important risk factor.
V.   Reactive atypia
Medium to large glands may display reactive atypia in the setting of
inflammation, ischemia and radiation. Such processes may lead to
glandular distortion and nuclear atypia which sometimes results in a pattern
that may be confused with prostatic intraepithelial neoplasia (PIN) and
large gland patterns of adenocarcinoma.
The important points to differentiate reactive atypia from malignant
condition is the identification of following features that includes
inflammation, infarction, and  intact  basal cell layer. The atypia associated
with reactive conditions may result in nuclei that appear hyperchromatic
and somewhat degenerate. In some cases, the nucleolar enlargement
associated with the reactive state may be more prominent and more
uniform than that seen with adenocarcinoma.  Presence of a residual basal
cell layer sometimes requiring confirmation with the 34βE12 stain are the
best clues to the benign nature of this condition.
VI. Prostatic metaplasic lesions
1.Mucinous metaplasia
Mucinous metaplasia usually occurs in the peripheral zone closed to
normal glands of the prostate. The glands that are lined by mucin abundant
tall columnar cells and small basal nuclei. It is necessary to find out
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mucinous metaplasia in order not to confuse it with intraluminal mucin
which is often identified with PAA85. The metaplastic cells are positive for
mucin staining (PAS, mucicarmine, and Alcian blue), and IHC staining of
PSA and PSAP.
2. Nephrogenic Adenoma
Nephrogenic adenoma is a benign lesion of the urothelial lined
organs from the renal pelvis to the urethra. Nephrogenic adenoma may be
observed in TURP specimens as urethral mucosa, and suburethral tissue
may be sampled during the TURP procedure. When nephrogenic adenoma
is present in the prostatic urethra and involves suburethral tissue and
seemingly infiltrates the prostatic parenchyma proper, it may potentially be
confused with a prostatic adenocarcinoma since proliferation of closely
packed small glands is the common histologic manifestation in this
condition.
3. Paneth cell-like metaplasia
Paneth cell-like metaplasia often represents a series of
differentiation, such as neuroendocrine differentiation, exocrine
differentiation, or intestinal Paneth cell differentiation. It is frequently
associated with HGPIN and PAA, particularly in the patients who
underwent radiotherapy or hormone therapy. It has lately been found that
AMACR may be strongly positive in benign prostatic acini with Paneth
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cell-like change86. To a certain extent, it is necessary to pay attention to
avoid misdiagnosis.
VII. Normal histoanatomic structures and non-neoplastic lesions that
may simulate adenocarcinoma of the prostate
1.Ejaculatory Ducts and Seminal Vesicle Tissue
Tissue fragments derived from seminal vesicles and ejaculatory
ducts are occasionally observed during examination of TURP or prostatic
needle biopsy specimens.
Epithelium of the ejaculatory duct and seminal vesicle contains
coarsely granular, yellow-brown lipofuscin pigment which is more
characteristic. It must be remembered, that prostatic adenocarcinoma also
rarely contains intracytoplasmic lipofuscin pigment which is finer and less
refractile when compared to seminal vesicle pigment.
The epithelial cells in the seminal vesicle and ejaculatory duct often
have large atypical, hyperchromatic nuclei; These structures often show
small glandular structures arranged in a back-to-back pattern, and therefore
they may be confused with a small acinar carcinoma.
2. Cowper gland and paraganglionic tissue
Tissue from bulbourethral Cowper glands may occasionally
present in TURP or needle biopsy specimens from the apex. Cowper gland
may be confused with a well-differentiated adenocarcinoma of the prostate;
however, the superficial similarity of Cowper gland to salivary glands, the
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bland nuclear features, loss of prominent nucleoli, increased
intracytoplasmic mucin, and negative immunoreactivity for PSA and PAP
suggests the correct diagnosis.
3.Hyperplasia of mesonephric remnants
Hyperplasia of mesonephric remnants is a rare yet small glandular
proliferation within the prostate gland, the severity of the diagnostic pitfall
being exemplified by a case misdiagnosed as cancer that resulted in a
radical prostatectomy that did not show evidence of cancer.
Microscopically, it is characterized by a lobular proliferation of
small tubular structures lined by a single layer of epithelium or by
infiltrating glands between muscle bundles and prostatic acini without a
stromal desmoplastic response. Variation in the size of the tubules is seen,
with occasional cyst formation, intratubular papillary proliferation, and
eosinophilic secretions within dilated glands. The acini are lobular, but can
be infiltrative and may be architecturally mistaken for adenocarcinoma.
4.Verumontanum Mucosal Gland Hyperplasia
Verumonatum mucosal gland hyperplasia (VMGH) is a small-gland
proliferation in the verumontanum,misdiagnosed as carcinoma.
VMGH has an expansile circumscribed growth pattern with glands
of small caliber arranged in a back-to-back fashion. Distinction from
cancer is usually not a problem when attention is paid to the cytologic
features at higher power. The glands have a layer of basal cells and
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corpora amylacea or orange-brown secretions, and the nuclei lack nuclear
enlargement  or conspicuous nucleoli.
ROLE OF IMMUNOHISTOCHEMISTRY IN PROSTATIC
LESIONS
The pathological process which affect prostate gland with sufficient
frequency are inflammation, benign nodular hyperplasia & tumours.
Prostatic lesions on routine hematoxylin & Eosin staining sometimes cause
diagnostic dilemma between benign and malignant lesions and especially
in premalignant lesions like atypical adenomatous hyperplasia and prostatic
intraepithelial neoplasia. There are number of benign small acinar lesions
in the prostate gland that may be difficult to differentiate from small  acinar
adenocarcinoma. An important diagnostic criterion in the differentiation is
the loss of basal cell layer in adenocarcinoma and its presence in the benign
lesions. Several immunohistochemical stains have been used to stain basal
cells of prostate against their markers eg. high molecular weight
cytokeratin(34βE12), p63.
I. Basal cell –associated markers
Basal cell associated markers  highlight basal cells present in benign
prostate glands and related benign, but architecturely atypical,
proliferations. Under hematoxylin & eosin staining, basal cells may be
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mimicked by prostatic stromal cells juxtaposed to the glandular basement
membrane, or by endothelial cells of blood vessels closely situated to
acini,and by tangentially sectioned neoplastic cells. Generally employed
basal cell markers are HMWCK (34βE12) and p63.
1. High molecular weight cytokeratin
High molecular weight cytokeratin (34βE12) is a cytoplasmic
marker that highlights intermediate cytokeratin filaments in glandular basal
cells and is specific for basal cells in prostate. It is also known CK903 and
targets CK1, CK2, CK10 and CK1487. There are some disadvantages of
34βE12 includes that (a) long term formalin fixation and formalin fixation
interval may affect its antigenicity. (b) Antigen retrieval methods may
affect its expression. (c) In Kalantari et al study, reported that the
sensitivity of 34βE12 is lower than p63 for differentiation of benign lesions
from adenocarcinoma88. Staining with HMWCK may vary between glands
of a benign glandular proliferation and the staining pattern may not be
cicumferential. So it has been used in combination with prostate cancer
specific marker α-methylacyl coenzyme A racemase or with other basal
cell associated markers rather than used alone.
2. p63
P63 is a basal cell marker and targets the p63 nuclear protein, which
is homologous to the TP53 tumour suppressor gene. It has been proven
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that it selectively stains the basal cell nuclei. It has been proven to regulate
growth and development in epithelium of the skin, cervix, breast and
urogenital tract as well as prostate.
P63 has similar applications to those of high molecular weight
cytokeratins in the diagnosis of prostatic adeno-carcinoma, but with certain
advantages. The advantages are (a) It stains a subset of 34βE12 negative
basal cells, (b) Less susceptible to the staining variability of 34βE12
(particularly in transurethral resection of prostate (TURP) specimens with
cautery artifact), and (c) It is easier to interpret because of its strong
nuclear staining intensity and low background. It seems to be more
sensitive in basal cell detection than 34βE12. However, false negative p63
stainings can occur and sometimes basal cells could be absent in small foci
due to the cutting procedure. Aberrant P63 expression may also be noted in
some prostatic adeno-carcinomas with unusual features, most representing
entrapped benign glands or intraductal spread of carcinoma with residual
basal cells.
3. CK5/6 basal cell marker
Another HMWCK is CK 5/6. It was reported to be a very sensitive and
specific marker of  prostatic basal cells, with fewer unsatisfactory results. It
is normally expressed  by  complex epithelium and a marker of mesothelial
cells and malignant mesothelioma as well as pancreatic, bile tract and
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mammary carcinomas. It reacts with prostatic basal cells not with tumour
cells or HGPINs. It is more effective than 34βE12 for ambiguous lesions.
Basal cell associated marker cocktails
Eventhough the use of single basal cell marker is sufficient for
diagnosing morphologically difficult prostatic lesions, p63 and HMWCK
34βE12 or CK5/6 cocktail provide intense positivity and highlight both
nuclei and cytoplasm89.
II. Epithelial markers
1.Cancer specific marker-AMACR
AMACR, an α-methylacyl coenzyme A racemase is also known
as P504S and it is involved in β-oxidation of branched-chain fatty acids
and fatty acid derivates. It is located in mitochondria and peroxisomes.
AMACR is generally expressed in the cytoplasm of cancer epithelial cells
and is normally negative in benign tissue.  However it can be expressed in
HGPIN as well as in benign lesions such as atrophy and adenosis. AMACR
reactivity can also be seen in secondary tumours involving the prostate
such as urothelial carcinoma and colonic adenocarcinoma. AMACR
expression may be negative in 5 to 25% of prostate carcinomas90. In some
variants of adenocarcinoma such as atrophic carcinoma, foamy gland
carcinoma and pseudohyperplastic carcinoma, AMACR expression can be
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negative91. So positive AMACR staining doesnot always indicate
carcinoma and negative staining does not rule out carcinoma.
Currently, AMACR is used as an additional IHC marker in
combination with p63 and high molecular-weight cytokeratins for the
diagnosis of prostate cancer. Interestingly, observed association of
decreased AMACR expression in localized PC with the worse disease
outcome and PSA recurrence, suggesting its possible use as a marker of
prognosis.
Treatment options and prognosis of prostatic adenocarcinomas and
benign lesions differ significantly, so they must be diagnosed with
accuracy. This requires application of immunohistochemical stains for
basal cells especially in morphological ambiguous cases (p63 shows
nuclear staining in basal cells of benign prostate lesions and no staining in
prostatic adenocarcinoma). A double immunohistochemical staining with
combination of p63 and AMACR has a very important diagnostic utility.
2.Cytokeratins
The cocktail of AE1 and AE3 detects both acidic (CK14-16 and CK
19) and basic (CK1-6 and CK8) cytokeratins. It is the most commonly and
universally used epithelial marker. It is useful in differentiating nonspecific
granulomatous prostatitis, crushed or marked inflammation and xanthoma
cells from high grade prostate cancer. In post therapy cases, CK AE1/AE3
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can be used in highlighting atrophic prostate cancer cells since it is not
suppressed by therapy.
III. Prostate lineage –specific markers
PSA and prostate-specific acid phosphatase (PSAP) are used to
confirm a prostatic acinar cell origin. It is  useful (1) To rule out non
prostatic carcinoma mimics such as seminal vesicle/ejaculatory duct,
cowper gland, hyperplastic mesonephric glands, nephrogenic adenoma and
paraganglionic tissue. (2) To differentiate unusual variants of prostatic
carcinoma such as ductal, mucinous and signet ring carcinoma (which
show positive staining for PSA and PSAP)  from secondary tumours
involving the prostate (which are negative for these markers).
Antibody cocktails
Recently, the cocktails combining basal cell associated markers and
AMACR are used in diagnosing morphologically difficult cases. The
antibody cocktails used are (a) AMACR , p63 and HMWCK 34βE12. (b)
AMACR/P63/CK5/6. (c) AMACR/p63. The triple or PIN cocktail
combines AMACR, p63 and HMWCK using 2 chromogens, red for
AMACR and brown for HMWCK and p63. This 3-antibody, 2- chromogen
cocktail has been considered as a simple and easy assay for routine use. It
has many advantages which include greater sensitivity for basal cells,
easier evaluation of atypical acini (due to different colored chromogen) and
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minimizing the potential loss of representation from evaluating a single
slide92,93. The PIN 4 cocktail which has the combination of
AMACR/HMWCK(CK5 and CK14) and p63, may be useful in diagnosing
prostatic intraepithelial neoplasia (PIN), especially in morphologically
difficult and limited tissue cases. P504S stains cytoplasm in prostatic
adenocarcinoma and atypical adenomatous hyperplasia whereas p63 and
HMW CKs stain normal and benign prostate glands.
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MATERIALS AND METHODS
Present study is a retrospective study to determine the effectiveness
of Immunohistochemistry in differentiating prostatic adenocarcinoma from
premalignant lesions and benign mimickers of prostatic adenocarcinoma.
The study was carried out in the department of pathology, Tirunelveli
medical college over a period of 2015-2017. Study material includes about
54 cases of prostatic lesions diagnosed in TURP specimens and prostatic
needle biopsies were collected. Since it is a retrospective study, blocks and
slides of prostatic lesions from 2013 to 2017 were collected.
Inclusion criteria
1 Cases that were diagnosed as prostatic adenocarcinoma, premalignant
lesions of prostate (High grade intraepithelial neoplasia, Low grade
intraepithelial neoplasia), benign mimickers of prostatic
adenocarcinoma (includes atrophy, adenosis, basal cell hyperplasia,
chronic prostatitis) in TURP specimens and prostatic needle biopsies.
2 Cases which had suspicious atypical foci or prostatic intraepithelial
neoplasia.
Exclusion criteria
1. Inadequate biopsy tissue sample
2. Poorly processed material
3. Autolysed specimen
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Materials Required
1 Blocks which contains formalin fixed paraffin embedded tissue of  TURP
and prostatic needle biopsy specimens, which were diagnosed as prostatic
adenocarcinoma, premalignant lesions of  prostate (High grade
intraepithelial neoplasia, Low grade intraepithelial neoplasia), benign
mimickers of prostatic adenocarcinoma(includes atrophy, adenosis, basal
cell hyperplasia, chronic prostatitis)
2 Hematoxylin and eosin stained tissue sections made from the blocks.
3 Postively charged slides for holding tissue sections for IHC
4 Chemicals for preparing antigen retrieval solutions and for wash buffers
5 Microoven for antigen retrieval.
6 Kit for performing immunohistochemistry which includes primary
antibody (P63 and AMACR) and universal kit
7 Microscope used for making gleason grading of prostatic adenocarcinoma
in hematoxylin and eosin stained slides and grading of IHC slides.
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METHODOLOGY
I.Collection of donor blocks and slides
The haematoxylin and eosin stained sections which were
prepared from formalin fixed paraffin embedded blocks of prostatic lesions
diagnosed in TURP and prostatic needle biopsies are collected. The
following cases are selected
1 Slides which contain prostatic adenocarcinoma, premalignant lesions of
Prostate (High grade intraepithelial neoplasia, Low grade intraepithelial
neoplasia), benign mimickers of prostatic adenocarcinoma(includes
atrophy, adenosis, basal cell hyperplasia, chronic prostatitis)
2 Slides which contain suspicious atypical foci and features of prostatic
intraepithelial neoplasia.
II.Preparation of haematoxylin and eosin slides
All the TURP and prostatic needle biopsy specimens were fixed in
10% formalin and were subjected to histopathological examination.
Formalin fixed paraffin embedded blocks were made. Sections of 2-4
micron thickness were made and routine staining with hematoxylin and
eosin was done.
Cases were selected after examining the slides. Gleason grading was done
for all prostatic adenocarcinoma cases according to the histological pattern.
Immunohistochemitry  using basal cell specific markers p63 and prostate
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cancer specific marker AMACR was done for all 54 cases including
Prostatic adenocarcinoma, Prostatic intraepithelial neoplasia, benign
mimickers of prostatic adenocarcinoma. Statistical analysis was done to
rule out expression of   p63 and  AMACR.
III.Immunohistochemistry
1.Section cutting
Sections were taken at 5 microns thickness on the surface of the
APES (3-aminopropyltriethoxysilane) coated slides. This was followed by
incubation of slides at 58-600c for one hour.
2.Antigen retrieval solution
We used antigen retrieval solution and a wash buffer as prescribed
by the manufacturer (PATH INSITU).
1 Tris EDTA at a pH of 9 .
2 Tris wash buffer at pH of  7.6.
3.Antigen retrieval
Many methods have been used for antigen retrieval which includes
Microwave method, and water bath, autoclave, proteolytic enzyme and
pressure cooker method. In our institution we followed antigen retrieval by
using microwave method as it produces even heating and less time
consuming with lesser disadvantages as compared to other methods.
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4. Procedure for immunohistochemistry as given by manufacturer
1 Section cutting and incubation is followed by Xylene wash (3 changes)
for 10minutes each.
2 Rehydrated in graded alchohol containing 100%, 80%, 70% for five
minutes each.
3 Rinsed in distilled water for 2minutes.
4 Antigen retrieval for 15-20 minutes in Tris-EDTA buffer.
5 Cooling for 15minutes.
6 Washed in TBS wash buffer- 3 changes 5minutes each.
7 Treated with endogeneous peroxide block for 7-10minutes.
8 Washed in TBS wash buffer- 3 changes 10minutes each.
9 Application of primary antibody (p63/AMACR) – 30 mins.
10 Washed in TBS wash buffer- 3 changes 10minutes each.
11 Add Target binder for 15 mins
12 Washed in TBS wash buffer- 3 changes 10minutes each
13 Application of HRP POLYMERASE for 15 mins.
14 Washed in TBS wash buffer- 3 changes 10minutes each.
15 Application of  Diamino-benzidine tetrachloride(DAB) chromogen (1
drop)and DAB buffer (1ml) for 5 mins.
16 Washed in distilled water – 2 changes.
17 Counterstaining with Harris Hematoxylin – 1dip/30seconds to impart
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background staining.
18 Wash in running tap water.
19 Place in xylene – 2 changes 5 minutes each.
20 Dehydrate in 100% alcohol – 5 minutes.
21 Mount the section with Dextrene phthalate xylene
22 Observation and grading under light microscope.
5. Grading of IHC stained sections:
After immunohistochemistry using p63 and AMACR was done, the
slides were examined under all the magnification with the help of light
microscopy and grading was done.
Interpretation of  p63 immunostaining
Immunostaining of p63 was interpreted as positive/negative. Positive
staining was graded as mild, moderate and strong according to percentage
of basal cells showing nuclear positivity. Positive staining was defined as
positive staining of  nuclei of basal cells. Positive  staining in  the foci in
question, was  taken as benignity and  negative staining of an entire
suspicious focus was taken as presumptive evidence of malignancy.
Pattern of positive staining considered as continuous or discontinuous was
also recorded to see  the difference in various non-malignant conditions.
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Table 1: Grading of p63 staining88
Percentage of cells
with positivity
Result Grading
0% Negative Negative
<5% Mild 1+
5-75% Moderate 2+
>75% Strong 3+
Interpretation of AMACR staining
AMACR staining were considered positive, in case of
circumferential, dark, diffuse or granular, cytoplasmic or luminal staining.
The percentage positivity was graded from 0 to 3+. IHC results were
negative if there was an absence of  staining or if only focal weak non-
circumferential fine  granular staining was seen with  absence of staining
in the adjacent benign glands.
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Table 2 : Grading of AMACR staining94
Percentage
of positivity
Result Grading
0% Negative Negative
1-10% Mild 1+
11-50% Moderate 2+
> 51% Strong 3+
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OBSERVATION AND  RESULTS
In this study there were total of 54 cases, out of these  45 were
TURP specimens and 9 were prostatic needle biopsies . Out of 54 cases,
24 cases were prostatic adenocarcinoma , 19 cases were low grade PIN, 3
cases were HGPIN, 2 cases were basal cell hyperplasia, 2 cases were
atrophy, 2 cases were adenosis and 2 cases were chronic prostatitis.
Table-3  Distribution of samples based on histopathological diagnosis
Histopath
diagnosis
Frequency Percent
Adenocarcinoma 24 44.44%
Prostatic intraepithelial
neoplasia 22 40.74%
Cancer mimickers 8 14.81%
Total 54 100.00%
This table shows that out of 54 cases, 24 cases are adenocarcinoma,
22 cases are prostatic intraepithelial neoplasia (19 Low grade PIN and 3
High grade PIN) and 8 cases are benign mimickers of adenocarcinoma
(includes 2 cases of  basal cell hyperplasia, 2 cases of atrophy, 2 cases of
adenosis, 2 cases of chronic prostatitis).
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Chart 1- Distribution of samples based on histopathological diagnosis
In this chart all 54 cases are divided into 3 categories.
(1) indicates prostatic intraepithelial neoplasia cases which are about 22.
(2) indicates adenocarcinoma cases which are about 24.
(3) indicates benign mimickers of adenocarcinoma which are about 8.
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Table 4- Age distribution in adenocarcinoma cases
This table shows that out of 24 prostatic adenocarcinoma cases,
20 cases are above 60 years of age with peak incidence in between 60 -70
years. Also there are no cases below the age group of 50 years.
S.NO
Age
(In years)
No of adenocarcinoma
Cases
1 <50 0
2 51-60 4
3 61-70 13
4 70-80 6
5 >80 1
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Chart 2- Age distribution in adenocarcinoma cases
This chart  shows that all the prostatic  adenocarcinoma cases are above 50
years of age with  peak incidence in between 61 to 70 years.
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Table 5-Age distribution in all cases (n=54)
(Age in years)
Histopathological
Diagnosis
<50 51-60 61-70 71-80 >80
Low gradePIN 2 3 11 2 1
High grade PIN 3
Adenocarcinoma 4 13 6 1
Basal cell hyperplasia 1 1
Atrophy 1 1
Adenosis 1 1
Chronic prostatitis 1 1
This table shows that all the cases are above the age group of 50
years except 2 cases with peak incidence in  between 60-70 years.
In our present study, mean age of all the cases is 66 + 8.18
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Chart-3 Age distribution in all cases (n=54)
This chart explains that out of 54 cases , 29 cases  are in the age
group of 61-70 years of age. It also indicates that all the prostate
adenocarcinoma(AC), prostatic intraepithelial neoplasia (PIN) and benign
mimickers of prostatic adenocarcinoma (BM) cases are  above 50 years of
age with less incidence (2 cases) below 50 years.
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Table-6  p63 immunoreactivity in adenocarcinoma of prostate and
cancer mimickers
Histopathological
diagnosis
No.of.cases
Grading of p63 positivity
0%
Negative
<5%
Mild
5-75%
Moderate
>75%
Strong
Adenocarcinoma 24 24 0 0 0
Low grade PIN 19 0 0 6 13
High grade PIN 3 1 0 2 0
Basal cell hyperplasia 2 1 1
Atropy
2 2
Adenosis 2 2
Chronic prostatitis
2 2
This table shows that all 24 adenocarcinoma cases show negative
staining for p63. All LGPIN cases show moderate to strong p63 positivity
for basal bells. Out of 3 HGPIN cases, 1 case shows negative staining and
2 cases show moderate p63 expression. All benign mimickers of
adenocarcinoma cases show moderate to strong positive p63 expression. In
our study 1 HGPIN case showed patchy basal cell staining for p63.
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Chart -4  Expression of p63 in adenocarcinoma cases
This chart  explains that all 24 adenocarcinoma cases show negative
staining for p63 (1-Negative, 2-Mild positive , 3-moderate positive, 4-
strong positive)
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Chart-5  p63 expression in prostatic intraepithelial neoplasia cases
This chart shows that out of  22 cases( 19 LGPIN and 3 HGPIN) ,
13 cases show strong positivity, 8 cases show moderate positivity and 1
case shows negative staining for p63. In this study one HGPIN case
shows patchy basal cell staining for p63 in the PIN foci. (1-Negative, 2-
Mild positive , 3-moderate positive, 4-strong positive)
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Chart-6  p63 expression in benign mimickers of adenocarcinoma cases
This chart shows that out of  8 benign mimickers of adenocarcinoma cases,
5 cases show moderate degree of positivity and 3 cases show strong
positivity for p63. (1-Negative, 2-Mild positive, 3-moderate positive,
4-strong positive)
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Table 7- Relationship between p63 expression and cases
Histopathological
Diagnosis
P63 expression
p valueNegative Positive
Non cancerous prostatic
Lesions
1 29
<0.0001
Adenocarcinoma 24 0
Statistical analysis was done using Pearson chi square test to find out
the  p value which showed significant value of about  <0.0001. It indicates
that there is a significant association between p63 expression and
noncancerous lesions of prostate.
We also measured the sensitivity and specificity of p63 expression in
dignosing prostatic adenocarcinoma  and cancer mimickers cases.
Sensitivity Specificity PPV NPV
100% 100% 100% 100%
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Table 8- AMACR immunoreactivity in adenocarcinoma and cancer
mimickers
Histopathological
diagnosis
No.of.
cases
Grading of AMACR expression
0%
Negative
1-10%
Mild
11-50%
Moderate
>51%
Strong
Adenocarcinoma 24 0 1 3 20
Low grade PIN 19 19
High grade PIN 3 3
Basal cell hyperplasia 2 1 1
Atrophy 2 2
Adenosis 2 2
Chronic prostatitis 2 2
This chart explains that all 24 adenocarcinoma cases show AMACR
positivity and all PIN cases show negative staining. Out of 8 benign
mimickers of prostatic adenocarcinoma cases, one basal cell hyperplasia
case shows strong AMACR expression and remaining 7 cases are negative
for AMACR expression.
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Chart-7 AMACR expression in Prostatic adenocarcinoma cases
This chart explains that out  of  24 adenocarcinoma cases ,20 cases
show strong AMACR expression, 3 cases exhibits moderate degree of
AMACR expression and 1 case shows mild AMACR expression.
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Chart-8 AMACR expression in cases with Prostatic intraepithelial
neoplasia
This chart shows that out of 22 Prostatic intraepithelial neoplasia
cases (19 Lowgrade PIN Cases and 3 High grade PIN cases), all cases
show negative AMACR expression.
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Chart-9 AMACR expression in benign mimickers of Prostatic
adenocarcinoma
This chart shows that out of 8 benign mimickers of adenocarcinoma
cases (2 Basal cell hyperplasia cases, 2 cases with atrophy, 2 cases with
adenosis and 2 cases with chronic prostatitis), 1 basal cell hyperplasia case
exhibits strong AMACR Expression and all other cases show negative
staining for AMACR.
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Table 9- Relationship of AMACR expression with cases
Histopathological
Diagnosis
AMACR Expression p value
Negative Positive
Non cancerous prostatic
Lesions
29 1
<0.0001
Adenocarcinoma 0 24
The  association between AMACR Expression and adenocarcinoma
cases was assessed using chi square test that showed p value of about
<0.0001 which is statistically significant.
We also measured the sensitivity and specificity of AMACR
expression in dignosing prostatic adenocarcinoma and cancer mimickers.
Sensitivity Specificity PPV NPV
100% 88% 96% 100%
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Correlation of  Gleason grade and  AMACR expression in prostatic
adenocarcinoma cases
In this study, prostatic adenocarcinoma cases are divided into 5
distinct groups according to Gleason grading95.
Group 1=Gleason score < 6,
Group 2=Gleason  score 3+4=7,
Group 3=Gleason score 4+3=7,
Group 4=Gleason score 8,
Group 5=Gleason score 9 & 10.
74
Table-10 Distribution of adenocarcinoma cases based on Gleason score
Gleason score Frequency
< 6 Group 1 8
3+4 Group 2 0
4+3 Group 3 3
8 Group 4 4
9 and 10 Group 5 9
This table shows that out of  24 prostatic adenocarcinoma cases, 8 cases are
in group1, no cases in group 2, 3 cases in group 3, 4 cases in group 4 and 9
cases in group 5.
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Chart-10 Distribution of adenocarcinoma cases based on Gleason
grading.
This chart explains that all 24 adenocarcinoma cases are divided into
5 groups based on Gleason score. Group 1 has 8 cases, Group 3 has 3
cases, Group 4 has 4 cases and Group 5 has 9 cases.
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Table 11-Correlation of Gleason score and AMACR expression
Gleason score
Number of
cases
AMACR expression
Mild Moderate Strong
<6 8 1 7
4+3=7 3 1 2
8 4 1 3
9 &10 9 1 8
This table shows that out of 24 prostatic adenocarcinoma cases,8
cases are  in group1, no cases in group 2, 3 cases in group 3, 4 cases in
group 4 and 9 cases in group 5. Of these, 19 cases showed strong AMACR
expression, 3 cases with moderate degree of expression and 1 case with
mild degree of expression. This table also indicates that strong AMACR
expression is noted irrespective of Gleason grade, which explains that
there is no correlation between AMACR expression and Gleason grading.
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Chart-11 Correlation of Gleason score grouping and AMACR
expression
This chart explains that correlation between AMACR expression and
Gleason grade. Out of 9 cases with high Gleason score (group5), 8 cases
show strong AMACR expression and 1 case shows moderate expression.
Out of 8 cases with low Gleason score, 7 cases exhibits strong expression.
It indicates that there is no association between Gleason score and
AMACR expression.
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Statistical analysis was done using pearson correlation test and
pearson chi square test. From which coefficient correlation and p value was
measured to find out whether there is any correlation between gleason
grading of prostatic adenocarcinoma cases and AMACR expression. It
showed  coefficient correlation=0.009 and p value=0.966, which indicates
that there is no correlation between them.
coefficient correlation p value
GLEASON SCORE AMACR 0.009 0.966
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DISCUSSION
Prostate cancer produces a major health problem, being the second
most common cancer in men. So early recognition and treatment is
necessary. Since the recognition of PSA as a screening tool, more and more
number of core biopsies were done leading to early recognition and
treatment of prostate cancer which resulted in reduced mortality. Even in
prostatic core biopsies, pathologists encounter a small focus of atypical
cells or benign mimickers of malignancy which make the diagnosis of
prostatic carcinoma difficult. The mimickers of malignancy includes the
conditions such as, atrophy, partial atrophy, post atrophic hyperplasia,
BCH, clear cell cibriform hyperplasia, adenosis, nephrogenic adenoma,
mesonephric hyperplasia and seminal vesicle.
In recent years, IHC has emerged as sensitive and specific
diagnostic tool in diagnosing morphologically difficult cases, thereby
increasing the diagnostic accuracy of prostatic cancer. The IHC markers
commonly used  are antibodies against basal cells such as p63, HMWCK
(34 βE12)  and  the prostatic adenocarcinoma specific marker AMACR .
Basal cell markers which includes HMWCK (34 βE12), CK 5/6
and p63 are very helpful for demonstration of basal cells because their
existence makes the diagnosis of invasive prostatic adenocarcinoma highly
unlikely96. But there are many limitations with the usage of basal cell
markers in the diagnosis of PC since some benign atypical conditions like
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Atypical adenomatous hyperplasia (AAH), HGPIN, post atrophic
hyperplasia (PAH) may also exhibit irregular or patchy staining, making
the diagnosis difficult.
Studies done by Angela wu and Lakshmi P kunju97, Giovanna et
al98 and Charles C Guo et al99 reported aberrant positive p63 expresssion in
cases of prostatic adenocarcinoma with atrophic features/basaloid features,
atypical basal cell proliferation, basal cell carcinoma and intraductal
carcinoma. So we should be very cautious in interpreting basal cell
immunostains in diagnosing prostatic adenocarcinoma.
Eventhough basal cell markers are an extremely useful adjunct, it is
important to use an additional cancer specific marker for adenocarcinoma,
having a high sensitivity and specificity for confirmation of the diagnosis.
Multiple studies have now evaluated the utility of AMACR
immunostain in the diagnosis of PC, making AMACR a useful
immunohistochemical marker for prostate cancer. AMACR expression has
also been noted in HGPIN, adenosis and even in benign prostatic glands
which limits its usage as a cancer specific marker. So AMACR is more
sensitive and specific when used in combination with basal cell markers.
In our present study we have used both p63 and AMACR
antibodies and demonstrated the expression of both these markers in
differentiating cancer mimickers and premalignant lesions from
adenocarcinoma.
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Grisanzio et al100, who performed p63 staining in 130 cases of
invasive prostate cancer and found p63 negativity in 126 (97%) cases. Four
cases showed p63 positivity in < 1% of tumour cells.
Parsons et al101, who studied p63 expression in a large series and
described strong diffuse p63 protein expression in basal cells of normal and
hyperplastic prostate glands, and patchy strong expression in proliferative
atrophy and HGPIN.
Kalantari et al88, studied p63 expression in 12 cases of adenosis ,
16 cases of atrophy and 10 HGPIN cases.All cases showed p63 positivity.
Also all the 38 adenocarcinoma cases evaluated in their study were p63
negative.
In Shah et al96 study, 2 out of 27 partial atrophy cases showed
p63 positivity.  Also Wang et al study exhibited that 30% of partial atrophy
cases  were p63 positive.
In Vladimir et al study102, they demonstrated p63 expression in
15 cases with severe morphological signs of chronic inflammation in
prostate which showed positive basal cell staining.
In our study we had 24 prostatic adenocarcinoma cases,22 PIN
cases and 8 cases of benign conditions which mimic adenocarcinoma. Out
of  8 cancer mimickers, 2 cases are prostate atrophy, 2 cases are adenosis,2
cases are basal cell hyperplasia and 2 cases are chronic prostatitis. Out of
22 PIN cases, 19 cases are LGPIN and 3 cases are HGPIN.
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Of these, 21 PIN cases (95%) and 8 cases(100%) of benign
mimickers of adenocarcinoma showed moderate to strong degree of
positive basal cell staining for p63. All 24 cases of adenocarcinoma (100%)
showed negative staining for basal cells.
The association between p63 expression and noncancerous prostatic
lesions is statistically significant as the p value is <0.0001. In this study,
p63 has 100% sensitivity and 100% specificity in diagnosing cancer
mimickers and adenocarcinoma cases. So it can be considered as a reliable
basal cell markerin distinguishing prostatic adenocarcinoma from
premalignant lesions and benign conditions which mimic carcinoma.
Zhou et al103 demonstrated that, of 115 prostate biopsies
diagnosed as atypical by an expert pathologist, 34 (30%) were changed to a
final diagnosis of cancer based on a positive AMACR immunostain. In our
study all 24 adenocarcinoma cases (100%) showed positive AMACR
expression. The association between AMACR expression and
adenocarcinoma cases is statistically significant as the p value is <0.0001.
In our study, AMACR has 100% sensitivity and 88% specificity in
diagnosing cancer mimickers and adenocarcinoma.
AMACR expression is also identified in 4-21% of benign
prostatic glands104,103 and up to 18-27% of cases of Adenosis. Yang et
al105, studied AMACR expression in 40 samples with AAH foci and found
that 33 (83%) showed negative staining, focal stainig in 4 cases and diffuse
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staining in 3 cases. In our study, both the 2 adenosis cases showed negative
AMACR expression.
Studies done by Jiang et al106, Luo et al107 and Rubin et al108,
reported that positive AMACR staining was noted in all Adenocarcinoma
and HGPIN cases.
Hosler and Epstein73, in their study of Basal cell hyperplasia cases
alone, reported that the immunohistochemical staining was useful for the
identification of the nature of basal cell proliferation. They found 100%
(7/7) positivity for p63 and complete negative expression for AMACR in
all those cases of basal cell hyperplasia.
Fatma El-Zahraa Salah El-DeenYassin et al109who studied on BCH
and HGPIN cases alone, noted the expression of  p63 and AMACR in 9
basal cell hyperplasia and 16 HGPIN cases. Of these, all basal cell
hyperplasia (100%) cases showed p63+ and AMACR-. Also all 16 HGPIN
cases (100%) showed  positive p63 expression, of these 3/16 (19%) cases
with continuous pattern of staining and 13/16 cases(81%) with fragmented
pattern of staining.
In our present study, we had 2 basal cell hyperplasia and 3 HGPIN
cases. Out of the 3 HGPIN cases, 2 cases showed positive p63 expression(1
with continuous staining pattern and other with patchy staining pattern) and
1 case showed  negative p63 expression Out of 2 BCH cases, both showed
p63 positivity and 1 out of 2 cases showed AMACR positivity.
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In contrast to previous studies, all the 3 HGPIN cases showed
negative AMACR expression and 1 out of 2 BCH cases showed positive
AMACR expression. So the HGPIN case which showed p63-/AMACR-
and the BCH case which showed  p63+/AMACR+ needs to be evaluated
further and followed up to rule out malignancy.
Vincent molinie et al110 in their study,found that all atrophic and
benign lesions showed 10–100% persistent basal cell staining  with p63
and all prostatic carcinomas were negative for p63.AMACR expression
was noted in 2% of normal glands (4/260) with a focal weak staining .
AMACR overexpression was noted in 97% of cancer cases with a
heterogeneous staining pattern from weak, moderate and strong intensity,
independently of the Gleason score (P=0.29). In our study, AMACR
expression was negative in normal benign glands.
Also Zhong jiang et al106, who compared Gleason grading with
AMACR expression in 137 prostatic adenocarcinoma cases and noted
strong positive expression of AMACR regardless of varying Gleason grade
with 100% sensitivity.
In our present study also, it showed that intensity of AMACR
expression did not correlate with the Gleason score(p=0.966 and
coefficient correlation=0.009).
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LIMITATIONS OF THE STUDY
1. Since our study is a retrospective study PSA values could not be collected
for more number of cases. PSA value was available only in 17/54 cases.
Hence the correlation of PSA values with the diagnosis of prostatic lesions
couldn’t be done.
2. In our institution there are less number of cancer mimicker and HGPIN
cases available for comparison of expression of these markers
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SUMMARY
This study includes a total of 54 cases with prostatic lesions
diagnosed from TURP specimens and prostatic needle biopsies. Of these
24 cases were adenocarcinoma, 19 cases were LGPIN, 3 cases were
HGPIN and remaining 8 cases were benign mimickers of adenocarcinoma
(2 atrophy, 2 adenosis, 2 chronic prostatitis and 2 BCH cases). We have
done IHC staining for all the cases using p63 and AMACR antibodies to
differentiate prostate adenocarcinoma from benign prostatic lesions which
mimic carcinoma. Also to find out the expression of these markers in
benign glands and premalignant lesions.
Out of 24 adenocarcinoma cases all showed p63-/AMACR+.
Negative staining  for p63 indicates that complete absence of basal cells in
adenocarcinoma. Of 8 benign mimickers of adenocarcinoma cases,7 cases
showed p63+/AMACR- and 1 Basal cell hyperplasia case showed
p63+/AMACR+. All the 19 LGPIN cases showed p63+/AMACR-. Out of
3 HGPIN cases,2 cases showed p63+/AMACR- and 1 case showed p63-
/AMACR-.
As in previous studies, p63 was positive in all BPH with LGPIN
cases, 8 cancer mimickers and 2 HGPIN cases. p63 was negative in all
adenocarcinoma cases. AMACR was positive in all adenocarcinoma cases
and negative in LGPIN cases and 7 cancer mimickers in our study.
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In contrast to previous studies, 1 BCH case was AMACR positive
and all 3 HGPIN cases were AMACR negative in our study.
In this study, both sensitivity and specificity of p63 was 100%
in cancer mimickers and adenocarcinomas. Sensitivity and specificity of
AMACR in cancer mimickers and adenocarcinoma was 100% and 88%
respectively. The association between p63 expression and noncancerous
prostatic lesions is statistically significant as the p value is <0.0001 and
also there is a statistically significant association present between AMACR
expression and adenocarcinoma cases as the p value is <0.0001.
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CONCLUSION
1. p63 is a 100% sensitive and 100% specific basal cell marker and can be
used in morphologically difficult cases which mimic adenocarcinoma.
AMACR has 100% sensitivity but 88% specificity in diagnosing the
prostatic lesions which mimic adenocarcinoma. So When we use both
these markers in combination the diagnostic accuracy can be improved.
2. There is no significant correlation between Gleason grading and
AMACR expression in adenocarcinoma cases ( p value =0.966).
3. Positive p63 expression and negative AMACR expression was noted in
all benign glands. All LGPIN cases showed p63 positive and AMACR
negative. Out of 3 HGPIN cases, 2/3 cases are p63 positive . So it can
be inferred that p63 is a reliable basal cell marker in diagnosing benign
and premalignant lesions and ruling out carcinoma.
4. We also conclude that, AMACR expression was negative in all 3
HGPIN cases in contrast to other studies. All adenocarcinoma cases
showed AMACR+/p63-. So AMACR marker may be used in
differentiating HGPIN and adenocarcinoma cases  in addition to basal
cell markers like p63.We also suggest that further study of AMACR
expression with more number of HGPIN cases is necessary.
COLOUR PLATES
FIGURE 1:A CASE OF PROSTATIC ADENOCARCINOMA –
H AND E IMAGE
FIGURE :2-STRONG POSITIVE AMACR EXPRESSION IN
ADENOCARCINOMA
FIGURE 3: MODERATE POSITIVITY FOR AMACR IN
ADENOCARCINOMA
FIGURE 4:MILD POSITIVITY FOR AMACR EXPRESSION IN
ADENOCARCINOMA
FIGURE 5: POSITIVE AMACR EXPRESSION IN ADENOCARCINOMA
WITH ADJACENT BENIGN GLANDS SHOWING NEGATIVE AMACR
STAINING.
FIGURE 6: -NEGATIVE P63 EXPRESSION IN TUMOUR CELLS OF
ADENOCARCINOMA
FIGURE 7: A CASE OF HIGH GRADE PROSTATIC INTRAEPITHELIAL
NEOPLASIA H & E IMAGE
FIGURE 8: FOCAL STRONG POSITIVE P63 EXPRESSION IN HGPIN
FIGURE  9: NEGATIVE AMACR EXPRESSION IN HGPIN
FIGURE 10: A CASE OF LOW GRADE PROSTATIC INTRAEPITHELIAL
NEOPLASIA H& E IMAGE
FIGURE 11:POSITIVE P63 EXPRESSION IN LGPIN FOCI
FIGURE 12-NEGATIVE AMACR EXPRESSION IN LGPIN
FIGURE 13:  A CASE OF PROSTATE ATROPHY H& E
LOW POWER IMAGE
FIGURE 14: A CASE OF PROSTATE ATROPHY H& E
HIGH POWER IMAGE
FIGURE:15 POSITIVE P63 EXPRESSION IN PROSTATE ATROPHY
LOW POWER IMAGE
FIGURE 16: POSITIVE P63 EXPRESSION IN PROSTATE ATROPHY
HIGH POWER IMAGE
FIGURE 17: NEGATIVE AMACR EXPRESSION IN PROSTATE ATROPHY
FIGURE :18 A CASE OF BASAL CELL HYPERPLASIA –H& E IMAGE
FIGURE 19: POSITIVE P63 EXPRESSION IN BASAL CELL HYPERPLASIA
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S.no PATH NO AGE INYEARS IP NO
SPECIMEN
RECEIVED USG FINDINGS
PSA
VALUE                 HPE
GLEASON
SCORE
IHC RESULT-
%EXPRESSION OF  p63 P63 EXPRESSION
IHC RESULT-EXPRESSION
OF AMACR
%positivity
ofAMACR
Expression
1 76/13 69 735 TURP Enlarged  prostate HGPIN 55% BASAL CELLS POSITIVE& PIN FOCI POSITIVE MODERATE PIN FOCI  NEGATIVE
2 184/13 78 3501 TURP Enlarged  prostate  LGPIN 60% BASAL CELLS POSITIVE& PIN FOCI POSITIVE MODERATE PIN FOCI NEGATIVE
3 209/13 62 3709 TURP Enlarged  prostate  LGPIN >75%CELLS POSITIVE & PINFOCI POSITIVE STRONG PIN FOCI NEGATIVE
4 611C/13 70 12603 TURP Nodularprostate  LGPIN >75%  CELLS POSITIVE  &PIN FOCI POSITIVE STRONG PIN FOCI NEGATIVE
5 735/13 67 17027 TURP Nodularprostate  LGPIN >75%  CELLS POSITIVE  &PIN FOCI POSITIVE STRONG PIN FOCI NEGATIVE
6 928/13 65 22828 TURP Nodularprostate  LGPIN >75%CELLS POSITIVE & PINFOCI POSITIVE STRONG PIN FOCI NEGATIVE
7 1222/17 65 26842 TURP Nodularprostate LGPIN >75%CELLS POSITIVE & PINFOCI POSITIVE STRONG PIN FOCI NEGATIVE
8 2554/13 55 53110 TURP Nodularprostate LGPIN >75% CELLS POSITIVE &PINFOCI POSITIVE STRONG PIN FOCI NEGATIVE
9 2579/13 70 52303 TURP Enlarged  prostate LGPIN 85%  CELLS POSITIVE& PINFOCI POSITIVE STRONG PIN FOCI NEGATIVE
10 2848/13 47 59321 TURP Enlarged  prostate LGPIN >75% CELLS POSITIVE & PINFOCI POSITIVE STRONG PIN FOCI NEGATIVE
11 3023/13 78 60464 TURP Enlarged  prostate LGPIN 50% CELLS POSITIVE & PINFOCI POSITIVE MODERATE PIN FOCI NEGATIVE
12 1208/14 50 21923 TURP Nodularprostate  LGPIN 70% CELLS POSITIVE & PINFOCI POSITIVE MODERATE PIN FOCI NEGATIVE
13 1574/14 72 23946 TURP Prostatomegaly ADENOCARCINOMA 3+2=5 TUMOUR CELLS-NEGATIVE NEGATIVE  3+POSITIVE 70%
14 1209/14 66 21923 TURP Enlarged  prostate  BASAL CELLHYPERPLASIA 60% BASAL CELLS POSITIVE MODERATE   NEGATIVE
15 1774/14 70 29868 TURP Nodularprostate LGPIN >75% BASAL CELLS POSITIVE&PIN FOCI POSITIVE STRONG PIN FOCI NEGATIVE
16 1923/14 55 32226 TURP Enlarged  prostate  LGPIN <5%  BASAL CELLS & PINFOCI POSITIVE MODERATE PIN FOCI NEGATIVE
17 2273/14 67 3835 TURP Enlarged  prostate   HGPIN BASALCELLS POSITIVE INPIN FOCI MODERATE PIN FOCI NEGATIVE
18 1037/14 70 15820 TURP         Grade 2prostatomegaly
ADENOCARCIN
OMA 4+3=7 TUMOUR CELLS-NEGATIVE NEGATIVE 2+ POSITIVE 15%
19 1417/14 67 23928 TURP Prostatomegaly ADENOCARCINOMA 4+5=9 TUMOUR CELLS-NEGATIVE NEGATIVE 3+ POSITIVE 80%
20 1616/14 85 25264 TURP Prostatomegaly ADENOCARCINOMA 5+4=9 TUMOUR CELLS-NEGATIVE NEGATIVE 3+ POSITIVE 65%
21 2182/14 80 34722 TURP     Grade 4prostatomegaly
ADENOCARCIN
OMA 4+3=7 TUMOUR CELLS-NEGATIVE NEGATIVE 3+POSITIVE 90%
22 3875/14 70 68114 TURP Prostatomegaly 7.6 ADENOCARCINOMA 3+2=5 TUMOUR CELLS-NEGATIVE NEGATIVE 3+POSITIVE 60%
23 563/15 84 4717 TURP Enlarged  prostate LGPIN 70% CELLS POSITIVE & PINFOCI POSITIVE MODERATE NEGATIVE
24 971/15 70 16715 TURP Enlarged  prostate  LGPIN >75%  CELLS POSITIVE &PINFOCI POSITIVE STRONG NEGATIVE
25 1534/15 67 26764 TURP Enlarged  prostate  LGPIN >75% CELLS POSITIVE &PINFOCI POSITIVE STRONG NEGATIVE
26 1697/15 70 31386 TURP Enlarged  prostate  LGPIN >75% CELLS POSITIVE & PINFOCI POSITIVE STRONG NEGATIVE
27 1700/15 60 30902 TURP enlarged  prostate  LGPIN 20%  CELLS POSITIVE & PINFOCI POSITIVE MODERATE NEGATIVE
28 1049/15 68 17263 TURP       Grade 3Prostatomegaly 9.4
ADENOCARCIN
OMA 2+3=5 TUMOUR CELLS-NEGATIVE NEGATIVE 3+POSITIVE 85%
29 1163/15 61 20033 TURP Prostatomegaly 8.6 ADENOCARCINOMA 2+3=5 TUMOUR CELLS-NEGATIVE NEGATIVE 3+POSITIVE 100%
30 2257/15 54 42023 TURP       Grade 4prostatomegaly 13.1
ADENOCARCIN
OMA 5+4=9 TUMOUR CELLS-NEGATIVE NEGATIVE 3+POSITIVE 75%
31 2375/16 67 40994 TURP Enlarged  prostate    HGPIN BASAL CELLS POSITIVE &PIN FOCI NEGATIVE NEGATIVE NEGATIVE
32 2377/16 67 38428 TURP Enlarged  prostate    LGPIN >75% CELLS POSITIVE &PINFOCI POSITIVE STRONG NEGATIVE
33 1354/16 80 24279 PROSTATEBIOPSY Prostatomegaly        >100
ADENOCARCIN
OMA WITH
PERINEURAL
INVASION
5+5=10 TUMOUR CELLS-NEGATIVE NEGATIVE 2+ POSITIVE 20%
34 1983/16 65 37321 PROSTATEBIOPSY Prostatomegaly 26.4
ADENOCARCIN
OMA WITH
PERINEURAL
INVASION
4+4=8 TUMOUR CELLS-NEGATIVE NEGATIVE 3+ POSITIVE 90%
35 2083/16 75 38395 TRUCUTBIOPSY Prostatomegaly 130
ADENOCARCIN
OMA 3+3=6 TUMOUR CELLS-NEGATIVE NEGATIVE 1+ POSITIVE 5%
36 598/17 69 6420 TURP        Grade2prostatomegaly 9
ADENOCARCIN
OMA 5+4=9 TUMOUR CELLS-NEGATIVE NEGATIVE 3+ POSITIVE 100%
37 2729/16 59 49164 PROSTATEBIOPSY
       Grade3
prostatomegaly 8.1
SUGGESTIVE OF
MALIGNANCY 2+3=5 TUMOUR CELLS-NEGATIVE NEGATIVE 3+ POSITIVE 60%
38 176/17 62 1823 PROSTATEBIOPSY Prostatomegaly 49
ADENOCARCIN
OMA 5+4=9 TUMOUR CELLS-NEGATIVE NEGATIVE 3+ POSITIVE 65%
39 2411/17 55 44748 TURP Prostatomegaly 12.6 ADENOCARCINOMA 5+5=10 TUMOUR CELLS-NEGATIVE NEGATIVE 3+ POSITIVE 95%
40 3977/16 60 75005 TURP Enlarged  prostate        ATROPHY 40 % BASAL CELLS POSITIVE MODERATE NEGATIVE
41 4024/16 76 69396 TURP Enlarged  prostate        ATROPHY 45 % BASAL CELLS POSITIVE MODERATE NEGATIVE
42 3288/16 57 45678 TURP Prostatomegaly       ADENOSIS >75% CELLS POSITIVE STRONG NEGATIVE
43 3292/16 75 59672 TURP Prostatomegaly       ADENOSIS >75% CELLS POSITIVE STRONG NEGATIVE
44 2744/13 55 57631 TURP Enlarged  prostate BASAL CELLHYPERPLASIA >75% BASAL CELLS POSITIVE STRONG >50% CELLS- 3+POSITIVE
45 3290/16 75 58133 TURP Enlarged  prostate CHRONICPROSTATITIS 60% BASAL CELLS POSITIVE MODERATE NEGATIVE
46 3289/16 65 46674 TURP Enlarged  prostate CHRONICPROSTATITIS 65% BASAL CELLS POSITIVE MODERATE NEGATIVE48
47 2714/17 74 47277 BIOPSY       Grade1prostatomegaly 52.6
SUGGESTIVE Of
PROSTATIC 3+2=5 TUMOUR CELLS NEGATIVE NEGATIVE 3+ POSITIVE 80%
48 2715/17 60 49564 BIOPSY Nodular prostate 8.7
SUGGESTIVEOF
PROSTATIC
ADENOCARCIN
OMA
3+3=6 TUMOUR CELLS-NEGATIVE NEGATIVE 3+ POSITIVE 100%
49 2531/17 62 46530 TURP       Grade 3prostatomegaly 7.4
ADENOCARCIN
OMA 4+5=9 TUMOUR CELLS-NEGATIVE NEGATIVE 3+POSITIVE 80%
50 2630/17 69 46525 TURP Enlarged prostatewith cystitis 9.1
ADENOCARCIN
OMA 5+4=9 TUMOUR CELLS-NEGATIVE NEGATIVE 3+POSITIVE 90%
51 2632/17 74 47961 BIOPSY Prostatomegaly 8.2 ADENOCARCINOMA 4+3=7 TUMOUR CELLS NEGATIVE NEGATIVE 3+POSITIVE 85%
52 2492/16 65 40647 TURP Prostatomegaly 13.1 ADENOCARCINOMA 4+4=8 TUMOUR CELLS NEGATIVE NEGATIVE 3+POSITIVE 70%
53 3266/17 68 48624 TURP Prostatomegaly ADENOCARCINOMA 3+5=8 TUMOUR CELLS NEGATIVE NEGATIVE 3+ POSITIVE 75%
54 3277/17 70 48923 BIOPSY Prostatomegaly ADENOCARCINOMA 5+3=8 TUMOUR CELLS NEGATIVE NEGATIVE 2+ POSITIVE 45%



